dorsaVi Limited (AU:DVL)
ASX:DVL
Want to see AU:DVL full AI Analyst Report?
Top Page
dorsaVi Limited
(Sydney:DVL)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.03
▲(13.33% Upside)
Action:ReiteratedDate:04/28/26
Overall score is held down primarily by weak financial performance (declining revenue, ongoing losses, and negative operating/free cash flow). Technical indicators also lean bearish (negative MACD and below longer-term moving averages), while valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Low financial leverage
A debt-to-equity of 0.055 gives dorsaVi structural financial flexibility: limited interest obligations and lower default risk. Over the next 2–6 months this reduces refinancing pressure, supports continued R&D and customer investment, and cushions cash burn while revenues recover.
Negative Factors
Declining revenue trend
Material revenue decline undermines scalability and weakens the business case for fixed-cost investments. Continued shrinkage compresses operating leverage, makes breakeven farther away, and increases reliance on funding to sustain operations over the coming 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
A debt-to-equity of 0.055 gives dorsaVi structural financial flexibility: limited interest obligations and lower default risk. Over the next 2–6 months this reduces refinancing pressure, supports continued R&D and customer investment, and cushions cash burn while revenues recover.
Read all positive factors
dorsaVi Limited (DVL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$48.40M
Dividend YieldN/A
Average Volume (3M)8.34M
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue Growth-25.87%
EPS Growth-150.00%
CountryAU
Employees34
SectorTechnology
Sector Strength88
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,210,028,400
10 Day Avg. Volume5,304,106
30 Day Avg. Volume8,343,384
Financial Highlights & Ratios
PEG Ratio1.57
Price to Book (P/B)3.65
Price to Sales (P/S)9.17
P/FCF Ratio-10.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
dorsaVi Limited Business Overview & Revenue Model
Company Description
dorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States. The company provides ViMove+, a clinical and sports solutions; ViSafe, a wearable sensor technology that tracks, analyzes,...
How the Company Makes Money
null...
dorsaVi Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 999.29K | 1.13M | 1.30M | 1.75M | 2.35M | 1.87M |
| Gross Profit | -1.75M | 971.82K | 1.18M | -798.43K | -1.45M | -1.74M |
| EBITDA | -4.87M | -1.82M | -1.60M | -1.88M | -1.53M | -2.29M |
| Net Income | -4.53M | -1.52M | -1.25M | -1.82M | -1.54M | -2.41M |
Balance Sheet | ||||||
| Total Assets | 8.13M | 3.97M | 2.18M | 2.69M | 3.36M | 5.42M |
| Cash, Cash Equivalents and Short-Term Investments | 4.95M | 2.29M | 478.10K | 878.72K | 449.70K | 2.80M |
| Total Debt | 135.68K | 156.89K | 190.17K | 321.85K | 1.18M | 1.18M |
| Total Liabilities | 2.15M | 1.14M | 1.16M | 1.01M | 2.13M | 2.95M |
| Stockholders Equity | 5.99M | 2.84M | 1.02M | 1.68M | 1.22M | 2.48M |
Cash Flow | ||||||
| Free Cash Flow | -2.68M | -956.83K | -622.08K | -1.02M | -2.25M | -2.36M |
| Operating Cash Flow | -2.68M | -956.83K | -600.90K | -967.41K | -2.15M | -2.27M |
| Investing Cash Flow | -299.61K | -304.00K | -21.18K | -51.65K | -100.34K | -85.41K |
| Financing Cash Flow | 6.72M | 3.08M | 227.06K | 1.45M | -92.25K | 3.47M |
dorsaVi Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
50 Neutral | AU$5.27M | 0.92 | 26.81% | ― | -17.34% | ― | |
44 Neutral | AU$3.78M | -0.88 | -152.47% | ― | 51.34% | 78.57% | |
42 Neutral | AU$48.40M | -2.36 | -102.57% | ― | -25.87% | -150.00% | |
41 Neutral | AU$6.66M | -0.53 | 209.30% | ― | -13.81% | -37.77% | |
39 Underperform | AU$4.09M | -0.35 | 61.09% | ― | -9.40% | 21.60% |
* Technology Sector Average
AU:DVL
dorsaVi Limited
0.04
0.03
300.00%
AU:X2M
X2M Connect Limited
0.01
-0.01
-50.00%
AU:HYD
Hydrix Limited
0.02
0.00
0.00%
AU:BCC
Beam Communications Holdings Limited
0.06
0.03
103.33%
AU:ZMM
ZIMI Ltd
0.01
0.00
0.00%
dorsaVi Limited Corporate Events
DorsaVi Targets Exoskeletons With Neuromorphic Sensor Strategy
Apr 27, 2026
DorsaVi has identified next-generation powered exoskeletons as a strategic application for its existing wearable motion sensing and neuromorphic semiconductor technologies. The company is initially targeting exoskeleton intelligence layers, human-...
DorsaVi validates RRAM–neuromorphic platform for next‑generation robotics and exoskeletons
Apr 20, 2026
DorsaVi Limited has completed technical validation showing that its RRAM memory technology operates effectively with its neuromorphic processing IP, forming a coherent ultra-edge hardware platform for robotics, exoskeletons and adaptive wearables....
dorsaVi Announces Administrative Change to Company Auditor
Apr 10, 2026
dorsaVi Limited has appointed MVAB Audit Pty Ltd as its new auditor, following the resignation of MVAB Assurance, with the change driven by the incorporation of the existing audit practice. The company emphasized that there will be no change to th...
DorsaVi Options Lapse, Trimming Potential Diluted Capital
Apr 9, 2026
DorsaVi Ltd has announced the expiry of 1,297,792 listed options with the code DVLAA, which lapsed without being exercised or converted on 8 April 2026. The cessation of these options marginally reduces the company’s potential diluted share ...
dorsaVi Advances On-Sensor Intelligence With Neuromorphic-Ready Firmware Upgrade
Mar 23, 2026
dorsaVi Limited has begun developing Sensor V6.5, a major firmware upgrade that adds on-sensor intelligence and neuromorphic-ready architecture to its existing wearable sensor platform. The update shifts more analytics and signal processing direct...
dorsaVi Secures Elite Sport and European Clinical Deals to Drive Edge AI Expansion
Mar 16, 2026
dorsaVi Limited has announced new commercial and clinical wins in the U.S. and Europe that it says materially accelerate its growth trajectory and reinforce its edge AI strategy. The company’s Onboard Sensor Processing technology is transfor...
dorsaVi forms elite advisory board to drive neuromorphic ‘ultra edge’ strategy
Mar 4, 2026
dorsaVi has formed a world‑class Technical Advisory Board to support its shift from research validation to commercial rollout of RRAM‑enabled neuromorphic sensor and robotics platforms. The board will guide execution of the companyR...
Major Investor Ceases to Be Substantial Holder in dorsaVi Limited
Mar 2, 2026
A substantial shareholder has notified dorsaVi Limited that it has ceased to be a substantial holder in the company as of 27 February 2026, marking a reduction in its relevant interest in the company’s voting securities. The change follows a...
dorsaVi Completes Neuromorphic Tech Licence Deal With 80m-Share Issue
Feb 27, 2026
dorsaVi Limited has issued 80,000,000 fully paid ordinary shares as part of completing its acquisition of third-party neuromorphic enabling technology licences, advancing a deal first flagged in November 2025. The company confirmed the shares were...
dorsaVi Seeks ASX Quotation for 80 Million New Shares
Feb 27, 2026
dorsaVi Ltd has applied for quotation on the ASX of 80 million new ordinary fully paid shares under its existing ticker DVL. The securities, issued on 27 February 2026, arise from transactions previously notified to the market, expanding the compa...
DorsaVi Swings to Larger Half-Year Loss Despite Stronger Balance Sheet
Feb 26, 2026
DorsaVi Limited, a provider of wearable sensor and motion analysis solutions for clinical, workplace, and sports applications, focuses on delivering objective biomechanical data to support injury assessment, risk management, and performance improv...
dorsaVi Updates Securities Trading Policy to Align With ASX Requirements
Feb 6, 2026
dorsaVi Limited has updated its Securities Trading Policy, in line with ASX Listing Rule 12.10, and made the revised policy available on its website. The board-authorised update reinforces the company’s governance framework around securities...
dorsaVi Accelerates US PT Rollout and Push Into AI and Neuromorphic Tech
Jan 28, 2026
dorsaVi reported a strong December quarter, with cash receipts from customers rising 50% quarter-on-quarter to $280,000, supported by rapid commercial scaling in the US physical therapy market where more than 100 new PT sites were onboarded under ...
dorsaVi Links with ITRI and NTU to Drive 22-nm RRAM Platform for Next-Gen AI Hardware
Jan 28, 2026
dorsaVi Limited has launched a multi-year collaboration with Taiwan’s Industrial Technology Research Institute (ITRI) and Nanyang Technological University (NTU) to advance its proprietary RRAM platform to the 22-nanometre technology node, bu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.